Zimmer Biomet Holdings, Inc. Website

Zimmer Biomet Holdings, Inc.

NYSE-ZBH

Company Overview

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

  • Name

    Zimmer Biomet Holdings, Inc.

  • CEO

    Ivan Tornos

  • Website

    www.zimmerbiomet.com

  • Sector

    Health Care Equipment and Supplies

  • Year Founded

    1927

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • Zimmer Biomet has made impressive progress in placing its Rosa robots in hospitals and ambulatory surgical centers, paving the way for higher-margin implant pull-through.

  • Orthopedic surgeons often resist efforts by hospitals or health systems to limit their autonomy (and brand choice), which is one major factor that has contributed to the consistent failure of most programs put forth by providers.

  • Zimmer has amassed an impressive portfolio of patents, owning or controlling approximately 4,500 issued patents and applications worldwide.

Bears Say

  • The scarcity of high-quality comparative effectiveness research data makes it more difficult for orthopedic companies to secure premium pricing at the same time payers and hospitals are raising the bar for cost-effectiveness.

  • While Zimmer's Persona knee system offers opportunities for further customization, it also means more complications for inventory management (without clear clinical benefit).

  • Zimmer Biomet must improve procedure volume and top-line growth so that operating leverage moves in the positive direction.

Source: Morningstar Analysis - Nov 05, 2025

What's happening

Nov 13, 2025 - Dec 13, 2025

Zimmer Biomet Holdings Inc Faces Mixed Signals Amidst Market Challenges

  • Analysts at Wolfe Research identify ZBH as a potential "turnaround trade" in the orthopedic sector.
  • The company's earnings report revealed net sales below expectations, raising concerns about future revenue growth.
  • Regulatory scrutiny and operational challenges overshadowed positive product developments for ZBH.

Over the past month, Zimmer Biomet Holdings Inc (ZBH) experienced a stock price increase of 1.7%, outperforming the S&P 500's return of -0.2%. This performance indicates relative strength in ZBH's market position during this period, driven by bullish sentiment from analysts who see it as a potential "turnaround trade." Anticipated product launches, including new knee replacement software and an iodine-coated hip offering set for release in Japan in 2026, contributed to this optimism.

However, significant challenges emerged that led to bearish sentiment throughout the month. Following its earnings report on November 5th, where net sales reached $2 billion—falling short of the consensus estimate of $2.01 billion—the stock faced considerable downward pressure. This disappointing result prompted lowered full-year organic revenue growth projections and investigations into possible violations of federal securities laws by Bronstein, Gewirtz & Grossman LLC and Levi & Korsinsky.

The announcement regarding FDA clearance for Zimmer’s ROSA® Knee system did not sufficiently alleviate investor concerns related to financial health or competitive positioning against rivals like Stryker Corporation. Analysts expressed skepticism regarding ZBH's ability to regain market share amid ongoing struggles in international markets and operational difficulties resulting from order cancellations.

While ZBH managed a slight overall gain over the month—outperforming both the S&P 500 by an impressive margin of 2% relative to its decline—and also exceeding Health Care sector performance by 0.9%, these gains were overshadowed by serious issues surrounding revenue forecasts and regulatory scrutiny that raised questions about its future trajectory. Zimmer Biomet Holdings Inc outperformed the Health Care (XLV) sector by 0.9%.

NYSE:ZBH